Browsing Tag
ESMO 2025
3 posts
Is Faron Pharmaceuticals (AIM: FARN) turning a corner? Bexmarilimab shows 85% ORR in HR-MDS as ESMO data boosts confidence
Faron Pharmaceuticals’ updated ESMO 2025 data shows 85% ORR and new biomarker insight for bexmarilimab in HR-MDS. Find out why this trial may redefine the biotech’s future.
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.
Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips
Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.